Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview

xlomafota13 shared this article with you from Inoreader Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview Via American Journal of Cancer Research Am J Cancer Res. 2021 May 15;11(5):1873-1894. eCollection 2021. ABSTRACT Numerous prostate cancer (PC) associated genes have been reported in previous genome-wide association studies. Elucidation of prostate cancer pharmacogenomics have enhanced studies into the impact of germline genetic changes on treatment, in addition to evaluating related genomic alterations and biomarkers in prostate tumor tissues. Currently, Abiraterone (Abi) is used as one of the therapeutic options for PC. In this article, germline variants that have been associated with responses to Abi in patients with advanced PC are summarized. These include biomarker genes such as CYP17A1, AR-V7, HSD3B1, SLCO2B1, SULT1E1, and SRD5A2 that are involved in homologous recombination, as well as in gene expression mutations in important signaling pathways, such as WNT and Abi metabolic pathways. PMID:34094659 | PMC:PMC8167691 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.